Neuromodulation Focused Company Axonics Gets 28% Price Target Bump By This Analyst On Solid Q2 Performance
[ad_1] Axonics Inc AXNX reported a 50% Y/Y increase in Q2 sales to $69 million, beating the consensus of $59 million. Sacral neuromodulation (SNM) revenue was $55.8 million, and Bulkamid…
SEC Charges 11 People In $300M Crypto Ponzi Scheme
[ad_1] The Securities and Exchange Commission has charged 11 people for their roles in creating and promoting an allegedly fraudulent crypto-focused pyramid & Ponzi scheme that raised more than $300 million…
Amgen (AMGN) To Fight Internal Revenue Service (IRS) After $10.7 Billion Tax Bill
[ad_1] Amgen Inc AMGN will fight Internal Revenue Service over the company’s international tax strategy and $10.7 billion in back taxes and penalties, Wall Street Journal reported. The IRS agency…
Why Kazia Therapeutics (KZIA) Shares Are Plunging Today
[ad_1] Kazia Therapeutics Limited KZIA said GBM AGILE, a pivotal study for paxalisib in newly diagnosed glioblastoma, did not meet pre-defined criteria for continuing to a second stage. Patients enrolled in…
Why Celyad Oncology (CYAD) Shares Are Surging Today
[ad_1] The FDA has lifted the clinical hold on Celyad Oncology SA’s CYAD CYAD-101-002 (KEYNOTE-B79) Phase 1b trial after the company made changes to the eligibility criteria for the trial. “We remain…